Newark, Delaware, January 8, 2019 – The year 2019 marks 24 years of growth for QPS, LLC, a leading global CRO focused on bioanalytics…
QPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, today announced the expansion of its U.S.-based Phase I clinical…
QPS Neuro and Pronexus Analytical announced formation of a joint partnership aiming to build their respective areas of expertise on unified experimental platforms and…
New capacity will support large-scale, Phase III drug trials QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support…
Study to be conducted at QPS facilities in Groningen, the Netherlands Kancera AB, a pharmaceutical development company currently focused on the treatment of cancer…
New, five-year facility offers greater financial flexibility QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and…
The first-in-human study with ACT017 will be conducted at QPS facilities in Groningen, the Netherlands. Acticor Biotech, a biotechnology company focused on the treatment…
Complementary world-class capabilities prime for accelerating cardiovascular drug development QPS Holdings LLC and G-CURE BV announce today that they have signed an agreement to…
Nomination a by-product of employee, client, vendor and community support Dr. Benjamin Chien, CEO of QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research…
Agreement aims to advance the hybrid LBA-LCMS workflow for biologics quantification SCIEX, a global leader in life science analytical technologies, and QPS Holdings, LLC…
